Perioperative NALIRIFOX in patients with resectable pancreatic ductal adenocarcinoma: The open-label, multicenter, phase II nITRO trial-Reference-Cited by-同舟云学术

Perioperative NALIRIFOX in patients with resectable pancreatic ductal adenocarcinoma: The open-label, multicenter, phase II nITRO trial

Published:2024-01 Issue: Volume:196 Page:113430
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Melisi Davide^ORCID,Zecchetto Camilla^ORCID,Merz Valeria^ORCID,Malleo Giuseppe,Landoni Luca^ORCID,Quinzii Alberto^ORCID,Casalino Simona^ORCID,Fazzini Federica,Gaule Marina,Pesoni Camilla,Casetti Luca,Esposito Alessandro^ORCID,Marchegiani Giovanni,Piazzola Cristiana,D’Onofrio Mirko,de Robertis Riccardo^ORCID,Gabbrielli Armando,Bernardoni Laura,Crino Stefano F.,Pietrobono Silvia^ORCID,Luchini Claudio^ORCID,Aliberti Camillo,Martignoni Guido,Milleri Stefano,Butturini Giovanni,Scarpa Aldo,Salvia Roberto,Bassi Claudio

Funder

Ministero della Salute

Ministero dell’Istruzione, dell’Università e della Ricerca

Associazione Italiana per la Ricerca sul Cancro

Università degli Studi di Verona

Servier

Ministry of Education and Merit

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference21 articles.

1. NCCN Clinical Practice Guidelines in Oncology - Pancreatic Adenocarcinoma - Version 2.2023. 〈https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf〉 (accessed June 19, 2023.

2. Five-year outcomes of FOLFIRINOX vs gemcitabine as adjuvant therapy for pancreatic cancer: a randomized clinical trial;Conroy;JAMA Oncol,2022

3. Prognostic relevance of the revised R status definition in pancreatic cancer: meta-analysis;Leonhardt;BJS Open,2022

4. Completion of adjuvant chemotherapy after upfront surgical resection for pancreatic cancer is uncommon yet associated with improved survival;Altman;Ann Surg Oncol,2019

5. Clinical trials of systemic chemotherapy for resectable pancreatic cancer: a review;Mavros;JAMA Surg,2021